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Plasmodium falciparum gametocyte 
dynamics after pyronaridine–artesunate 
or artemether–lumefantrine treatment
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Abstract 
Background: Artemisinin-based combinations differ in their impact on gametocyte prevalence and density. This 
study assessed female and male gametocyte dynamics after treating children with uncomplicated Plasmodium falci-
parum malaria with either pyronaridine–artesunate (PA) or artemether–lumefantrine (AL).
Methods: Kenyan children with uncomplicated Plasmodium falciparum malaria were included and randomly 
assigned to PA or AL treatment. Filter paper blood samples were collected as a source of RNA for quantitative reverse-
transcription PCR (qRT-PCR) and nucleic acid sequence based amplification (QT-NASBA) to detect female gametocytes 
(targeting Pfs25 mRNA). Male gametocytes were detected by qRT-PCR (targeting PfMGET mRNA). Duration of gameto-
cyte carriage, the female and male gametocyte response and the agreement between qRT-PCR and QT-NASBA were 
determined.
Results: The mean duration of female gametocyte carriage was significantly longer for PA (4.9 days) than for AL 
(3.8 days) as estimated by QT-NASBA (P = 0.036), but this difference was less clear when determined by Pfs25 qRT-PCR 
(4.5 days for PA and 3.7 for AL, P = 0.166). qRT-PCR based female gametocyte prevalence decreased from 100% (75/75) 
at baseline to 6.06% (4/66) at day 14 in the AL group and from 97.7% (83/85) to 13.9% (11/79) in the PA group. Male 
gametocyte prevalence decreased from 41.3% (31/75) at baseline to 19.7% (13/66) at day 14 in the AL group and from 
35.3% (30/85) to 22.8% (18/79) in the PA group. There was good agreement between Pfs25 qRT-PCR and QT-NASBA 
female gametocyte prevalence (0.85, 95% CI 0.82–0.87).
Conclusions: This study indicates that female gametocyte clearance may be slightly faster after AL compared to 
PA. Male gametocytes showed similar post-treatment clearance between study arms. Future studies should further 
address potential differences between the post-treatment transmission potential after PA compared to AL.
Trial registration This study is registered at clinicaltrials.gov under NCT02411994. Registration date: 8 April 2015. https ://
clini caltr ials.gov/ct2/show/NCT02 41199 4?term=pyron aridi ne-artes unate &cond=Malar ia&cntry =KE&rank=1
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Background
Since artemisinin-based combination therapy (ACT) 
became widely adopted as first-line treatment for uncom-
plicated Plasmodium falciparum malaria, it considerably 
contributed to the decline of the disease burden [1–4]. 
However, resistance against commonly used artemisinin-
based combinations is rising in South-East Asia and the 
potential spread to African countries is a major public 
health concern [5, 6]. New drugs are under development 
that offer possible alternatives to currently used arte-
misinin-based combinations. One of these alternatives 
is the fixed-dose combination therapy pyronaridine–
artesunate (PA), which is found to be well tolerated and 
efficacious for the treatment of uncomplicated P. falci-
parum malaria and the blood stage of Plasmodium vivax 
malaria [7–12]. Mild and transient increases in transami-
nases are the main safety concern [11].
So far, the effect of PA on the transmission stages of P. 
falciparum (gametocytes), has not been extensively stud-
ied in the clinical setting. In vitro data are contradicting: 
a strong gametocytocidal effect of pyronaridine against 
stage II–IV gametocytes has been found [13], but was not 
confirmed elsewhere [14]. Delves et  al. reported activ-
ity of pyronaridine against stage V gametocytes in vitro, 
although only at concentrations close to cytotoxic lev-
els, suggesting limited clinical relevance [15, 16]. With 
the increasing efforts to reduce malaria transmission, it 
becomes highly important to evaluate not only the poten-
tial of ACT to cure the asexual stage of the parasite, but 
also their effect on gametocytes. ACT is generally effec-
tive against asexual stages and immature gametocytes, 
but its activity against mature gametocytes is limited [14, 
17–19]. However, differences between artemisinin-based 
combinations in the gametocyte response after treatment 
exist. A recent meta-analysis showed that the appearance 
of gametocytaemia in patients without gametocytes at 
baseline was lower after artemether–lumefantrine (AL) 
and artesunate-mefloquine (AS-MQ) compared to dihy-
droartemisinin–piperaquine (DP) and artesunate-amodi-
aquine (AS-AQ) [20]. Among patients with gametocytes 
at baseline, clearance was faster after AS-MQ and slower 
after DP, compared to AL. This meta-analysis by the 
Worldwide Antimalarial Resistance Network (WWARN) 
hypothesized that the non-artemisinin partner drug is 
a relevant determinant for differences in the post-treat-
ment gametocyte response.
To accurately evaluate the gametocyte response after 
ACT treatment, molecular tools are informative since 
post-treatment gametocyte densities are often below 
the detection threshold of microscopy [21]. Quantita-
tive Nucleic Acid Sequence Based Amplification (QT-
NASBA) is a sensitive and reliable technique for the 
detection of submicroscopic gametocytes, targeting the 
female-specific Pfs25 [22, 23]. Recently, a sex-specific 
quantitative reverse transcriptase PCR (qRT-PCR) has 
been developed and evaluated, differentiating between 
female (Pfs25) and male (PfMGET) gametocytes [24]. 
This differentiation may be important, because the 
minority male population (normally 3–5 females to 
1 male) was shown in  vitro to be more sensitive than 
females to a range of anti-malarial drugs [15]. Thus, 
faster clearance of the male gametocyte population 
during or after treatment might sterilize the infection, 
while the female-dominated gametocyte density may 
not be reduced to the same extent [25]. The sex-specific 
qRT-PCR can be used to investigate both male and 
female gametocyte dynamics in clinical trials.
In this study, the QT-NASBA and qRT-PCR based 
female specific gametocyte response after PA-treat-
ment was compared to that after AL. Furthermore, 
qRT-PCR was used to evaluate and compare male and 
female gametocyte dynamics. Finally, the agreement 
between Pfs25 qRT-PCR and QT-NASBA for the detec-
tion of female gametocytes was determined.
Methods
Study design
This observational study was part of a phase III rand-
omized clinical trial investigating the efficacy and safety 
of PA compared to AL in Kenyan children with uncom-
plicated P. falciparum malaria [26]. The study was con-
ducted at St. Jude’s Clinic, Mbita, Western Kenya, from 
October 2015 to June 2016 and from January to August 
2017. Ethical approval was obtained from the Ethi-
cal Review Committee of the Kenya Medical Research 
Institute (KEMRI) (NON-SSC no. 479, registered at 
clinicaltrials.gov under NCT02411994). Children aged 
6  months to 12  years seeking care at the clinic were 
eligible to participate if they were living within 10  km 
range from the study clinic and had microscopically 
confirmed P. falciparum mono-infection with a para-
sitaemia between 1000 and 200,000/µl. Exclusion cri-
teria were signs and symptoms of complicated malaria, 
non-P. falciparum or mixed Plasmodium infection, a 
history of hepatic and/or renal impairment, a haemo-
globin (Hb) concentration < 6 g/dL, severe malnutrition 
(defined as having a weight-for-age or height-for-age 
z-score of < − 3) [27], having received anti-malarial 
therapy in the previous 2 weeks, known hypersensitiv-
ity to artemisinins, previous participation in this study, 
current participation in other anti-malarial drug inter-
vention studies or not being available for follow-up. 
Written informed consent from a parent or guardian 
was required for study participation, assent was sought 
from children able to understand the study.
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Procedures
Study participants were randomized to receive a 3-day 
course of either artemether–lumefantrine (AL, Novartis, 
Basel, Switzerland) or pyronaridine–artesunate (PA, Shin 
Poong Pharmaceutical Company, Seoul, South Korea). 
All study staff except the pharmacists responsible for 
drug administration were blinded to treatment alloca-
tion. Dosing was body-weight dependent and drugs were 
administered according to manufacturer’s instructions 
(Additional file  1) with food (mandazi—a type of fried 
bread) or milk. For PA, children < 20  kg received gran-
ules dissolved in lemonade. Children ≥ 20 kg received the 
tablet formulation. In the AL group, all children received 
tablets.
Participants returned to the study clinic on 1, 2, 3, 7, 
14, 28 and 42  days after start of treatment. Blood sam-
ples were taken by finger-prick at all time-points. Hb was 
determined on day 0, 3, 7 and 28 by HemoCue (Ängel-
holm, Sweden). Giemsa-stained thick smears were used 
for determination and counting of asexual parasites 
and gametocytes, according to WHO procedures [28]. 
Thick-and-thin blood smears were prepared and read 
by local expert microscopists. A slide was considered 
negative when 100 high-power fields were examined at 
1000 × magnification and no parasites were observed. 
Parasitaemia was determined from thick smears by 
counting the number of parasites against 200 leukocytes, 
with the assumption of 8000 leukocytes/µl blood. When 
the number of parasites after counting 200 leukocytes 
was < 100, counting continued up to 500 leukocytes.
Female specific Pfs25 QT-NASBA and sex-specific 
Pfs25 and PfMGET qRT-PCR were used for gametocyte 
detection on day 0, 3, 7 and 14. To perform these assays, 
2 × 50  µl finger-prick blood was collected on Whatman 
903 protein saver cards (GE Healthcare, Chicago, USA), 
dried at room temperature for 24  h, packed individu-
ally with silica and stored at − 20  °C until shipment to 
the Netherlands. Nucleic acid extraction was done by 
Nuclisens EasyMag (bioMérieux, Marcy-l’Étoile, France) 
and DNA/RNA was stored at − 70  °C. QT-NASBA was 
performed as previously described [22], with minor 
modifications. The reaction mixture (5  µl) and sample 
(2.5 µl) were incubated for 2 min at 65  °C and 2 min at 
41  °C. Enzyme was added (2.5  µl) and the reaction was 
allowed to run for 30  min at 41  °C. Quantification was 
done using standard curves of  103 to  10−1 gameto-
cytes/µl, which were produced from in vitro cultures as 
reported [22]. qRT-PCRs were performed as previously 
described, using sex-specific standard curves  (103 to 
 10−2 gametocytes/µl) for quantification [24]. To produce 
these separate standard curves, male and female game-
tocytes were isolated by fluorescence activated cell sort-
ing using a transgenic parasite line expressing male and 
female specific fluorescence markers [29]. Samples were 
declared negative for both QT-NASBA and qRT-PCR if 
the estimated gametocytaemia was < 0.02 gametocytes/µl 
(1 gametocyte/50 µl sample) [30].
Outcomes
The primary outcome was the mean duration of female 
gametocyte carriage in the PA arm compared to the AL 
arm, based on QT-NASBA. Secondary outcomes were: 
the qRT-PCR based mean duration of female gametocyte 
carriage, the QT-NASBA and qRT-PCR based female 
gametocyte circulation time, the QT-NASBA based 
area under the curve (AUC) of female gametocyte den-
sity over time (gametocytes/µl−1 days), and gametocyte 
prevalence and density on day 3, 7 and 14 as determined 
by QT-NASBA and Pfs25/PfMGET qRT-PCR. Finally, the 
agreement between QT-NASBA and Pfs25 qRT-PCR for 
the detection but not quantification of female gameto-
cytes was determined.
Statistical analysis
Stata software version 14.0 (Stata Corporation, Texas, 
USA) and SAS version 9.4 (SAS Institute Inc, NC, USA) 
were used for statistical analyses. A deterministic com-
partmental model, as previously published, was fitted to 
determine the duration of female gametocyte carriage 
and gametocyte circulation times [31]. The AUC was 
determined as described previously and log10-trans-
formed [32]. Linear regression was used to compare the 
log AUC in the PA group to that in the AL group, adjust-
ing for log10-transformed baseline gametocyte density. 
The Wilcoxon rank-sum test was used for between-group 
comparisons of gametocyte density on day 0, 3, 7 and 14. 
A Chi square or Fisher’s exact test was used to compare 
between-group gametocyte prevalences on day 0, 3, 7 
and 14. The agreement between Pfs25 qRT-PCR and QT-
NASBA was determined by calculating the weighted con-
cordance correlation coefficient (CCC) based on variance 
components, taking repeated measures into account [33, 
34].
Results
Study population and baseline characteristics
A consecutive subset of 160 children from the main clini-
cal trial participated in the present study. Of these 160 
participants, 85 received PA and 75 received AL (Fig. 1). 
Nine participants did not complete follow-up (day 14) in 
the AL group: four withdrew consent, three moved away 
from the study area and two missed their day 14 visit. In 
the PA group, six participants did not complete follow-
up: three missed their day 14 visit, one discontinued due 
to repeated vomiting, one moved away from the study 
area and one had a treatment failure on day 7.
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Baseline characteristics were similar between interven-
tion groups (Table  1). QT-NASBA and Pfs25 qRT-PCR 
based female gametocyte prevalence and density at base-
line were comparable and higher than PfMGET qRT-PCR 
male estimates. As expected, microscopy based preva-
lence was lower compared to the molecular methods 
and children with microscopy confirmed gametocytes 
at baseline had significantly higher Pfs25 QT-NASBA 
gametocyte density compared to those without micro-
scopically detected gametocytes (P < 0.001, Wilcoxon 
rank-sum test).
Gametocyte carriage after PA and AL
QT-NASBA based female gametocyte prevalence at day 
3 was 37.0% (30/81) in the PA group and 31.0% (22/71) in 
the AL group (P = 0.433). At day 7, prevalence decreased 
to 21.7% (18/83) in the PA group and 16.7% (12/72) in 
the AL group (P = 0.430). Prevalence at day 14 was 15.2% 
(12/79) in the PA group and 7.58% (5/66) in the AL group 
(P = 0.156). Female gametocyte prevalence estimates 
were highly similar when assessed by Pfs25 qRT-PCR 
(Fig. 2, Table 2).
While prevalence estimates were comparable between 
QT-NASBA and qRT-PCR, some differences in density 
measurements were observed. As can be seen in Fig.  2, 
the decrease in density over time is clearer by qRT-PCR 
as compared to QT-NASBA, especially in the PA group. 
In the AL group, the QT-NASBA based female gameto-
cyte density decreased from a median of 6.36 gameto-
cytes/µl (IQR 1.19–22.2) at baseline to 1.45 gametocytes/
µl (IQR 0.65–1.69) at day 14. However, in the PA group, 
the median female gametocyte density estimated by QT-
NASBA in gametocyte positive samples did not decrease 
over time and even appeared to increase slightly: 3.23 
gametocytes/µl (IQR 0.68–18.1) at baseline versus 6.19 
gametocytes/µl (IQR 2.11–27.2) at day 14. Given that 
the median gametocyte density is only determined over 
gametocyte positive individuals, the median density on 
day 3, 7 and 14 is not necessarily assessed over the same 
individuals used to determine the baseline gametocyte 
- Missed day 14 visit: n=3
- Moved outside study area: n=1
- Treatment failure day 7: n=1
Completed day 14:
n= 79
- Consent withdrawn: n=2
- Moved outside study area: n=2
- Missed day 14 visit: n=2
Completed day 14:
n= 66
Screened:
n= 971
Enrolled:
n= 160
Assigned to AL:
n= 75
Assigned to PA:
n= 85
Excluded: n= 811
No Plasmodium infecon: n= 570
Parasitaemia <1000 p/µl: n= 149
P. malariae coinfecon: n= 63
Parasitaemia >200,000 p/µl: n= 16
Previous study parcipaon: n=7
Living outside study area: n=3
Already on anmalarial medicaon: n=1
Only gametocytes detected: n=1
Complicated malaria: n=1
Completed day 7:
n= 83
Completed day 7:
n= 72
- Rescue treatment aer 
repeated voming: n=1
- Missing day 7 sample: n=1*
- Consent withdrawn: n=2
- Moved outside study area: n=1
*A day 14 sample was available for this parcipant.
Fig. 1 Participant flow. Schematic presentation of patient screening, inclusion and follow-up for the present study
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density. To investigate whether this apparent increase 
over time in the PA group was due to an absolute increase 
within individuals, the median QT-NASBA based game-
tocyte density on day 0 for individuals still positive on 
day 14 was calculated and found to be 113.0 (IQR 21.0–
252). Thus, the median female gametocyte density for 
participants in the PA group gametocyte positive on day 
14 decreased from baseline to day 14 and the apparent 
rise in density as estimated by QT-NASBA could not be 
explained by an absolute increase within individuals, but 
is rather a difference between the population positives on 
day 0 and that on day 14.
The mean duration of female gametocyte carriage as 
estimated by QT-NASBA was significantly longer in the 
PA group (4.92 days, 95% CI 4.10–5.73), compared to the 
AL group (3.77  days, 95% CI 3.08–4.47) (P = 0.036). By 
qRT-PCR, the mean duration of female gametocyte car-
riage was also longer in the PA group (4.46 days, 95% CI 
3.72–5.20), compared to the AL group (3.74  days, 95% 
CI 3.04–4.44), but this difference was not significant 
(P = 0.166). Similarly, the QT-NASBA based mean game-
tocyte circulation time was longer for PA (1.34 days, 95% 
CI 1.12–1.56) compared to AL (0.96 days, 95% CI 0.81–
1.12) (P = 0.003). This was also the case for the qRT-PCR 
based mean gametocyte circulation time (PA: 1.38 days, 
95% CI 1.18–1.58 and AL: 1.04 days, 95% CI 0.89–1.20, 
P = 0.004) (Fig.  3 and Table  3). The AUC, on the other 
hand, was not different between treatment arms (Table 3, 
P = 0.617 after adjustment for baseline gametocyte den-
sity), possibly explained by the slower gametocyte clear-
ance in the PA group, but considerable contribution of 
the higher baseline gametocyte density to the AUC in the 
AL group.
Effect of PA and AL on male and female gametocytes
qRT-PCR was used to differentiate between male and 
female gametocyte responses after PA and AL. At base-
line, female gametocytes were detected in 97.7% (83/85) 
of participants in the PA group and 100% (75/75) of the 
participants in the AL group (P = 0.499). This prevalence 
decreased to 13.9% (11/79) on day 14 in the PA group 
and 6.06% (4/66) in the AL group (P = 0.122) (Fig. 2). At 
baseline, the male prevalence was lower compared to the 
female prevalence: 35.3% (30/85) in the PA group and 
41.3% (31/75) in the AL group (P = 0.433). In both groups 
the decrease in male gametocyte prevalence was less 
substantial than that of female prevalence (male gameto-
cyte prevalence 22.8% (18/79) in the PA group and 19.7% 
(13/66) in the AL group on day 14 (P = 0.652) (Fig. 4).
The median female density decreased from 2.88 
(IQR 0.85–5.24) gametocytes/µl at baseline to 0.58 
(IQR 0.30–1.66) on day 3 in the PA group. In the AL 
group, female baseline density was 1.94 gametocytes/
µl (IQR 0.77–5.35), which decreased to 0.30 (IQR 
0.14–0.62) on day 3. By day 14, median female gameto-
cyte density was 0.33 (IQR 0.14–6.42) in the PA group 
and 0.12 (IQR 0.08–0.90) in the AL group (P = 0.322) 
(Table 2). Median male density, on the other hand, did 
not decrease over time and even appears to increase 
slightly. Similar to the analysis of QT-NASBA den-
sity in the PA group as described above, the appar-
ent increase of male gametocytes over time was 
investigated. The median gametocyte density on 
day 0 for individuals still positive on day 14 was cal-
culated and found to be 9.44 (IQR 0.18–45.7) in the 
PA group and 10.1 (IQR 0.81–36.5) in the AL group. 
Thus, the median gametocyte density for participants 
Table 1 Baseline characteristics of study participants at enrollment
Data are: a Percentage % (n/N), b Median and IQR or c Mean and 95% CI
Pyronaridine–artesunate Artemether–lumefantrine
N 85 75
Malea 54.1 (46/85) 49.3 (37/75)
Age (years)b 7.0 (4.2–9.0) 6.0 (3.4–9.8)
Hb (g/dL)c 11.8 (11.4–12.2) 11.7 (11.2–12.2)
Temperature (°C)c 37.6 (37.4–37.9) 37.4 (37.1–37.7)
Fever (temperature > 37.5 °C)a 55.3 (47/85) 48.0 (36/75)
Asexual parasite density (p/µl)b 28,800 (12,000–68,640) 29,280 (12,000–67,680)
Gametocyte prevalence—microscopya 2.35 (2/85) 5.33 (4/75)
Gametocyte prevalence—QT-NASBAa 95.3 (81/85) 94.7 (71/75)
Gametocyte density—QT-NASBA (p/µl)b 3.23 (0.68–18.1) 6.36 (1.19–22.2)
Gametocyte prevalence—Pfs25 qRT-PCRa 97.7 (83/85) 100 (75/75)
Gametocyte density—Pfs25 qRT-PCR (p/µl)b 2.88 (0.85–5.24) 1.94 (0.77–5.35)
Gametocyte prevalence—PfMGET qRT-PCRa 35.3 (30/85) 41.3 (31/75)
Gametocyte density—PfMGET qRT-PCR (p/µl)b 0.94 (0.11–14.1) 0.48 (0.21–10.1)
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gametocyte positive on day 14 decreased from baseline 
to day 14 in both treatment groups (P = 0.01 for both 
PA and AL groups, Wilcoxon signed rank test). This 
illustrates also for male gametocytes that the apparent 
rise in density could not be explained by an absolute 
increase within individuals, but is rather a difference 
between the population positives on day 0 and that on 
day 14.
Fig. 2 Female gametocytes by Pfs25 QT-NASBA and qRT-PCR. a Gametocyte prevalence determined by QT-NASBA. b Gametocyte density 
determined by QT-NASBA. c Gametocyte prevalence determined by qRT-PCR. d Gametocyte density determined by qRT-PCR. 95% confidence 
intervals are presented for prevalences. Density is presented as median (IQR) for gametocyte-positive individuals only. Samples were considered 
negative if gametocyte levels were < 0.02/µl. AL artemether–lumefantrine, PA pyronaridine–artesunate
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Agreement between Pfs25 qRT‑PCR and QT‑NASBA
The agreement between binary female prevalence out-
comes of Pfs25 qRT-PCR and QT-NASBA was calculated 
using the CCC variance components method. Only sub-
jects with a complete dataset were included (140 par-
ticipants and 560 samples). Out of 560, 12 samples were 
positive by QT-NASBA but not by qRT-PCR. Similarly, 
10 samples were positive by qRT-PCR but negative by 
QT-NASBA. The two tests were in agreement for the 
remaining 538 samples (209 positive and 329 negative). 
The CCC was 0.85 (95% CI 0.82–0.87), indicating good 
agreement between Pfs25 qRT-PCR and QT-NASBA for 
the detection of female gametocytes.
Discussion
This is the first paper describing kinetics of submicro-
scopic gametocytes after PA treatment using molecular 
detection methods in comparison with the most widely 
used first-line treatment for malaria in Africa, AL. The 
duration of female gametocyte carriage and gametocyte 
circulation time appeared to be slightly longer for PA 
compared to AL. There were no indications that PA or 
AL preferentially cleared male gametocytes.
The failure of conventional anti-malarials, including 
ACT, to clear circulating mature gametocytes may allow 
persisting malaria transmission in the week(s) following 
treatment [35]. Gametocyte clearance time may thus be a 
relevant indicator of the transmission-blocking potential 
of anti-malarial drugs. Although it has been observed that 
some persisting gametocytes may not be viable [36], cur-
rent evidence suggests that a comparison of anti-malarial 
drugs on gametocytocidal properties would reach simi-
lar conclusions on their relative transmission blocking 
effects [18, 35–37]. The microscopy-based gametocyte 
clearance time has previously been compared between 
PA and AL, but no difference between the two drugs was 
found [7, 10]. Since microscopy is notoriously insensitive 
for gametocyte detection, molecular methods provide 
more accurate estimates of post treatment gametocytae-
mia [38]. Importantly, it has been shown that submicro-
scopic gametocytes may allow onward transmission to 
mosquitoes [39]. In the present study, gametocytes were 
detected by microscopy in only 3.75% (6/160) of study 
participants at baseline, compared to 95.0% (152/160) 
by QT-NASBA. This contrast is even higher than in pre-
vious studies and emphasizes the underestimation of 
gametocyte prevalence by microscopy [38].
Different effects of ACT on the gametocyte response 
have previously been reported and in a recent meta-anal-
ysis AL was shown to be better in preventing the micro-
scopic occurrence of gametocytes shortly after treatment 
compared to DP or AS-AQ [20]. A point of caution when 
Table 2 Female and  male gametocyte prevalence 
and density
* P-values represent between group differences. Prevalence differences were 
tested with the Chi squared or Fisher’s Exact test. Differences in gametocyte 
density were tested with the Wilcoxon rank-sum test
Data included: a female gametocyte positive individuals, b male gametocyte 
positive individuals, c male and/or female gametocyte positive individuals
Pyronaridine–
artesunate
Artemether–
lumefantrine
P value*
Pfs25 QT-NASBA prevalence, % (no./No.)
 Day 0 95.3 (81/85) 94.7 (71/75) 1.000
 Day 3 37.0 (30/81) 31.0 (22/71) 0.433
 Day 7 21.7 (18/83) 16.7 (12/72) 0.430
 Day 14 15.2 (12/79) 7.58 (5/66) 0.156
Pfs25 QT-NASBA density, median (IQR)a
 Day 0 3.23 (0.68–18.1) 6.36 (1.19–22.2) 0.229
 Day 3 3.86 (0.33–16.4) 3.73 (0.33–6.91) 0.630
 Day 7 2.82 (1.17–33.5) 0.74 (0.23–12.9) 0.150
 Day 14 6.19 (2.10–27.2) 1.45 (0.65–1.69) 0.092
Pfs25 qRT-PCR prevalence, % (no./No.)
 Day 0 97.7 (83/85) 100 (75/75) 0.499
 Day 3 30.9 (25/81) 33.8 (24/71) 0.699
 Day 7 19.3 (16/83) 16.7 (12/72) 0.674
 Day 14 13.9 (11/79) 6.06 (4/66) 0.122
Pfs25 qRT-PCR density, median (IQR)a
 Day 0 2.88 (0.85–5.24) 1.94 (0.77–5.35) 0.568
 Day 3 0.58 (0.30–1.66) 0.30 (0.14–0.62) 0.039
 Day 7 0.78 (0.33–15.5) 0.28 (0.16–0.83) 0.126
 Day 14 0.33 (0.14–6.42) 0.12 (0.08–0.90) 0.322
PfMGET qRT-PCR prevalence (%) (no./No.)
 Day 0 35.3 (30/85) 41.3 (31/75) 0.433
 Day 3 34.6 (28/81) 36.6 (26/71) 0.792
 Day 7 31.3 (26/83) 30.6 (22/72) 0.918
 Day 14 22.8 (18/79) 19.7 (13/66) 0.652
PfMGET qRT-PCR density, median (IQR)b
 Day 0 0.94 (0.11–14.1) 0.48 (0.21–10.1) 0.920
 Day 3 2.55 (0.21–11.0) 0.82 (0.17–5.07) 0.341
 Day 7 3.23 (0.21–8.95) 1.22 (0.19–11.5) 0.551
 Day 14 1.81 (0.30–11.2) 1.51 (0.66–6.91) 0.779
Total qRT-PCR prevalence, % (no./No.)
 Day 0 97.7 (83/85) 100 (75/75) 0.499
 Day 3 42.0 (34/81) 43.7 (31/71) 0.841
 Day 7 32.5 (27/83) 31.9 (23/72) 0.920
 Day 14 25.3 (20/79) 21.2 (14/66) 0.560
Total qRT-PCR density, median (IQR)c
 Day 0 3.23 (0.86–7.54) 2.24 (0.91–6.13) 0.642
 Day 3 1.20 (0.24–11.0) 1.06 (0.11–5.21) 0.248
 Day 7 3.47 (0.26–15.5) 1.69 (0.27–12.3) 0.631
 Day 14 1.66 (0.30–14.6) 1.34 (0.55–7.00) 0.662
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interpreting the results of this meta-analysis, is the fact 
that sensitivities of parasites to the drugs fluctuated 
over the years and drug efficacy is setting dependent. 
However, there is agreement in literature that, based on 
both microscopy as well as molecular gametocyte detec-
tion, the duration of gametocyte carriage is significantly 
shorter after AL treatment, compared to DP [20, 35]. In 
the present study, the duration of gametocyte carriage 
and gametocyte circulation time were surprisingly short 
compared to other studies in the same area [35, 37]. 
While the day 3 QT-NASBA female gametocyte preva-
lence was 31.0% (22/71) for AL and 37.0% (30/81) for 
PA, others reported day 3 QT-NASBA prevalences > 50% 
after AL treatment among those positive at baseline [35, 
37]. Previous studies in sub-Saharan Africa, using the 
same model to assess gametocyte clearance and circula-
tion time, found a duration of gametocyte carriage after 
AL of 12.4 days in a trial with similar inclusion criteria to 
the present study [40] and of 19.7 days in a trial includ-
ing patent gametocyte carriers [41]. These gametocyte 
carriage estimates are 3–5 fold longer compared to the 
present study. A possible explanation for this observa-
tion is the relatively low median gametocyte density at 
baseline in the present study. Alternatively, the process of 
storing and extracting RNA from filter papers may have 
resulted in a suboptimal yield and underestimated game-
tocyte prevalence during follow up. Despite the shorter 
clearance estimates compared to other reports, there are 
no indications that this observation affected the compari-
son between PA and AL in the present study.
Baseline prevalence of female gametocytes (estimated 
by qRT-PCR) was 98.8% (158/160), while male base-
line prevalence was only 38.1% (61/160). This is in con-
trast to the data presented by Stone et al. [24], from the 
same study site, where both female and male prevalence 
were 100% as estimated by the same qRT-PCR. How-
ever, the study by Stone et al. included only participants 
with microscopically detectable gametocytes, while being 
gametocyte positive by microscopy was uncommon in 
the present study. This resulted in median baseline qRT-
PCR-based gametocyte densities of 2.9/µl (PA) and 1.9/
µl (AL) for female gametocytes and 0.9/µl (PA) and 0.5/
Fig. 3 Duration of female gametocyte carriage and gametocyte circulation time. Rounds represent the mean duration of female gametocyte 
carriage (in days) and their error bars the upper and lower limit of the 95% CI. Triangles represent the mean female gametocyte circulation time (in 
days) and their error bars the upper and lower limit of the 95% CI. AL artemether–lumefantrine, PA pyronaridine–artesunate
Table 3 Estimates female gametocyte carriage, circulation time and area under the curve (AUC)
* Adjusted for baseline gametocyte density
Pyronaridine–artesunate Artemether–lumefantrine P‑value
Pfs25 QT-NASBA
 Duration of gametocyte carriage (days), mean (95% CI) 4.92 (4.10–5.73) 3.77 (3.08–4.47) 0.036
 Circulation time (days), mean (95% CI) 1.34 (1.12–1.56) 0.96 (0.81–1.12) 0.003
 AUC (g/µl−1 day), median (IQR) 0.52 (0.105–2.771) 0.79 (0.177–3.150) 0.617*
Pfs25 qRT-PCR
 Duration of gametocyte carriage (days), mean (95% CI) 4.46 (3.72–5.20) 3.74 (3.04–4.44) 0.166
 Circulation time (days), mean (95% CI) 1.38 (1.18–1.58) 1.04 (0.89–1.20) 0.004
Page 9 of 11Roth et al. Malar J  (2018) 17:223 
µl (AL) for males. Working with such low densities, with 
presumably a female biased sex-ratio at baseline, it is not 
unlikely that part of the samples with low density female 
gametocytaemia at baseline had male densities below 
the detection threshold, which may explain the differ-
ence in baseline prevalence between male and female 
gametocytes.
No evidence of faster male compared to female game-
tocyte clearance was found. In fact, the present data 
suggest that even though the proportion of participants 
with male gametocytes at baseline was lower than that 
with female gametocytes, males may actually be cleared 
slower. Previous studies that examined gametocyte 
sex ratio after DP or SP-AQ alone or with primaquine 
observed that during the course of follow-up gameto-
cyte sex ratios became more female-biased while pri-
maquine initially resulted in a male-biased sex ratio 
[24, 36]. In microscopy-based studies a female biased 
gametocyte response after various artemisinin-based 
combinations was commonly observed [42, 43]. In vitro 
results also indicate a more pronounced effect of most 
anti-malarial drugs on male compared to female game-
tocytes. For example, the percentage inhibition of acti-
vation by artemether and artesunate was found to be 
approximately 39 and 10 times higher, respectively, for 
males than for females [15]. The difference between the 
qRT-PCR used in the present study and the in vitro sys-
tem used by Delves et al. is that the latter evaluates the 
gametocytes’ ability to form gametes rather than the 
presence of mRNA. Whether the qRT-PCR can detect 
mRNA from nonviable gametocytes is unknown [40]. 
Both the in vitro and the mRNA results can be accurate 
if male gametocytes are more affected by the ACT than 
females, but remain present in the circulation during the 
time of sampling as intact nonviable gametocytes [24]. 
Thus, despite the clear added value of molecular tech-
niques like QT-NASBA and qRT-PCR, functional assays 
that determine gametocyte fitness or infectivity remain 
crucial in assessing transmission-blocking properties of 
anti-malarial drugs.
The apparent increase in male density (and female den-
sity in the PA arm as estimated by QT-NASBA) could not 
be explained by an absolute increase within individuals, 
but rather reflects a difference between the population 
positives on day 0 and that on day 14. Stone et  al. per-
formed a similar analysis and reported a small decrease 
of male density after DP treatment (from 3.8/µl at base-
line to 0.9/µl at day 7) [24]. Both studies had low baseline 
male gametocyte density, but estimates were approxi-
mately five times higher in the study by Stone et al. Base-
line densities close to the detection limit could lead to 
an increase in density by chance and this could possibly 
Fig. 4 Male gametocytes by PfMGET qRT-PCR. a Gametocyte prevalence, including 95% confidence intervals. b Gametocyte density, presented 
as median (IQR) for gametocyte-positive individuals only. Samples were considered negative if gametocyte levels were < 0.02/µl. AL artemether–
lumefantrine, PA pyronaridine–artesunate
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explain the difference in density over time between the 
two studies. Additionally, a study by Dicko et al. found a 
higher baseline density of male gametocytes and showed 
a more distinct decrease over time compared to both the 
present study and Stone et al. [24, 36].
A good level of agreement between QT-NASBA and 
Pfs25 qRT-PCR female gametocyte prevalence was 
observed. This confirms data from a previous study 
where both assays were shown to be suitable to detect 
and quantify submicroscopic levels of gametocytes, 
although the reproducibility of qRT-PCR was found to be 
better than that of QT-NASBA [30].
A limitation of the present study is that gametocyte 
infectiousness to mosquitoes could not be established. 
This was due to an infection of the established mos-
quito colony with Microsporidia species, which has been 
shown to inhibit the survival of Plasmodium in mosqui-
toes [44]. Since only mosquito feeding assays can pro-
vide evidence on the transmissibility of gametocytes, an 
assessment of infectivity could not be done. Future stud-
ies should further address potential differences between 
the post-treatment transmission potential after PA com-
pared to AL.
Conclusions
This study provides important data on the submicro-
scopic gametocyte response after PA compared to AL 
treatment of uncomplicated P. falciparum malaria. These 
data may contribute to estimates of impact differences 
between artemisinin-based combinations, for example 
based on a model that demonstrated a higher reduc-
tion of clinical episodes using long-acting combinations 
in high transmission settings, while combinations with 
shorter half-lifes but more pronounced gametocytocidal 
effects were shown to be more suitable for low-transmis-
sion settings [45].
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